Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Conexeu Sciences Inc. - Common Stock (NQ:CNXU)

4.780 +0.100 (+2.14%)
Streaming Delayed Price Updated: 11:48 AM EDT, Sep 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Conexeu Sciences Inc. - Common Stock

News headline image
A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
From Equity Insider
Via GlobeNewswire
News headline image
The Biggest Winners Don't Compete in a Category. They Rewrite It. One Company Is Betting It Can Too.
Issued on behalf of Conexeu Sciences Inc. 
From American News Group
Via GlobeNewswire
News headline image
The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For
News Provided by USA News Group on behalf of Conexeu Sciences Inc. 
From USA News Group
Via GlobeNewswire
News headline image
Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It
News Provided by Biotech Insider on behalf of Conexeu Sciences Inc. 
From Biotech Insider
Via GlobeNewswire
News headline image
Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One
Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU) 
From American News Group
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Gainers China Pharma Holding (AMEX:CPHI) shares moved upwards by 67.6% to $1.03 during Wednesday's regular session. The market value of their outstanding shares is at $24.9 million. Conexeu Sciences... 
Via Benzinga
News headline image
A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next
From Energy Metal News
Via GlobeNewswire
News headline image
A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
From Biotech Insider
Via GlobeNewswire
News headline image
The Aesthetics Giants Just Confirmed “Ozempic Face” Is Real — and a Newly Public Regenerative Player Wants to Compete for It
From Biotech Insider
Via GlobeNewswire
News headline image
Regenerative Medicine’s Next Chapter: Inside the Race to Make the Body Rebuild Itself
From Biotech Insider
Via GlobeNewswire
News headline image
The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding It
From World Street Intelligence
Via GlobeNewswire
News headline image
A Fresh FDA Catalyst Is Putting Regenerative Wound Care in Focus
Issued on behalf of Conexeu Sciences Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Before the IPO: 4 Companies That Rewarded Investors Who Got In Early ↗
Weiss Ratings analyst Chris Graebe outlines how Regulation A offerings let retail investors access private companies like FJET, NUCL, and CNXU before their public listings. 
Via MarketBeat
Topics Initial Public Offering
News headline image
After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead
Issued on behalf of Conexeu Sciences Inc. 
From Biotech Insider
Via GlobeNewswire
News headline image
The Newest Name on Nasdaq Wants to Help the Body Rebuild Itself
From Energy Metal News
Via GlobeNewswire
News headline image
A Reno Biotech Just Rang the Nasdaq Bell — Here’s Why the Whole Regenerative-Medicine Tape Is Worth Watching
Issued on behalf of Conexeu Sciences Inc. 
From World Street Intelligence
Via GlobeNewswire
News headline image
Conexeu Sciences Commences Trading on Nasdaq Under Ticker Symbol "CNXU"
Reno, Nevada--(Newsfile Corp. - May 21, 2026) - Conexeu Sciences Inc. (Nasdaq: CNXU) ("Conexeu" or the "Company"), a biotechnology company advancing tissue... 
Via Newsfile
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.